ATAI News

Allied Trust Insurance Selects BriteCore and Goes Live to Unify Operations and Accelerate Scalable Growth

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

Successfully Navigating Trade Mark Disputes: Tactics and Remedies to Objections, Oppositions, and Challenges (ONLINE EVENT: June 11, 2026)

Trade Mark Registry Proceedings at the UKIPO Training Course (ONLINE EVENT: May 13, 2026)

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

Attain Reports Second Consecutive Year of Triple-Digit Enterprise Growth, Scaling B2B Adoption and Advancing the Outcomes Era

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day